and are currently undergoing clinical development. These
agents induce rapid resolution of lymphadenoapathy and
a transient increase of lymphocytosis due to mobilization of
CLL cells into the peripheral blood. However, after several
months of continuous therapy, response can be achieved in
a substantial number of patients